Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI9X5U
|
|||
| Drug Name |
AAV-hTERT
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Aging [ICD-11: MG2A] | Phase 1 | [1] | |
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 1 | [1] | ||
| Critical limb ischemia [ICD-11: BD4Y; ICD-9: 459.89] | Phase 1 | [2] | ||
| Company |
Libella Gene Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | . | [2] |
| Telomerase reverse transcriptase (TERT) | Target Info | . | [1] | |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04133649) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for the Treatment of Aging: AAV- hTERT. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04110964) Evaluation of Safety and Tolerability of Libella Gene Therapy (LGT) for Critical Limb Ischemia: AAV- hTERT. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.